Retatrutide

Overview

Retatrutide is an investigational synthetic peptide designed as a triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptor pathways. It is one of the most closely watched metabolic research compounds because it combines three incretin and energy-balance signalling pathways in a single molecule.

Molecular Class

Synthetic peptide / incretin-based triple hormone receptor agonist.

Mechanism

Retatrutide is designed to activate glucose-dependent insulinotropic polypeptide receptor, glucagon-like peptide-1 receptor, and glucagon receptor pathways. This combined receptor profile makes it different from single GLP-1 agonists and dual GIP/GLP-1 agonists.

Research Areas

• Obesity research
• Metabolic signalling research
• Type 2 diabetes research
• Liver-fat and MASLD research
• Appetite and satiety pathway research
• Cardiovascular risk-factor research
• Energy expenditure research
• Incretin pharmacology research

Research Status

Retatrutide remains an investigational compound in active clinical development. Lilly is studying it across several Phase 3 programs, including obesity, type 2 diabetes, sleep apnea, osteoarthritis, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease.

Market Demand

Global demand is driven by obesity, metabolic disease, GLP-1, and next-generation incretin research. China-based peptide manufacturers frequently list retatrutide in wholesale vial formats for international research buyers.